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1

INTRODUCTION

Fluoroscopy equipment is used to observe or guide
moving objects such as internal organs, contrast agents,
catheters, and guidewires within the body to diagnose

and treat disease. Procedure times range from several seconds to multiple hours, and fluoroscopes range
from small, mobile C-arms used to image extremities,
to complex single- or bi-plane angiography systems.
These more complex fluoroscopes are used to guide
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performance of fluoroscopically guided interventional
(FGI) procedures, and help to provide lifesaving diagnostic and therapeutic services for patients. However,unlike simpler procedures commonly accomplished
using general or mobile C-arm fluoroscopes, long and
complex FGI procedures can exceed radiation thresholds for tissue reactions. Proper identification, follow-up,
and management of patients receiving high doses from
FGI procedures are essential parts of patient care due
to the slowly developing nature of radiation-induced tissue reactions. Recent standards and requirements from
accrediting bodies such as The Joint Commission (TJC)
and state regulatory agencies have brought focus to this
issue, requiring hospitals to record patient fluoroscopy
exam dose indices and to establish committees, policies,
and procedures for reviewing those data and providing
patient follow-up as appropriate. These standards are
in addition to TJC’s updated fluoroscopy sentinel event
standard, which requires identification and investigation
of severe tissue effects.
Many organizations and societies have provided guidance and resources for managing patient dose, including the National Council on Radiation Protection and
Measurements (NCRP), the Conference of Radiation
Control Program Directors (CRCPD), the Department
of Veterans Affairs, the Society of Interventional Radiology (SIR), and multiple cardiology societies under
the umbrella of the American College of Cardiology
Task Force on Expert Consensus Decision Pathways.1–5
This AAPM practice guideline aims to outline the role
of the diagnostic qualified medical physicist (QMP),
as defined by AAPM Policy Number PP 1-J “Definition of A Qualified Medical Physicist,” in practical
patient dose management for FGI procedures.6 This
role includes helping facilities set up policies related
to dose management, including pre-procedure patient
consent, intra-procedure dose index level notification,
and post-procedure follow-up for potential tissue reactions. Suggestions for methods of complying with TJC
standards and various state regulatory requirements for
tracking radiation use,setting dose index thresholds,and
analyzing dose index data are provided, along with a
discussion of the challenges posed by these requirements. The QMP’s role in helping facilities comply with
TJC’s updated “radiation overdose” sentinel event standards by investigating severe tissue reactions is also discussed. Related fluoroscopy topics that may fall under
the QMP’s oversight, such as operator credentialing and
occupational radiation exposure monitoring are briefly
discussed.

2

TISSUE REACTIONS

Tissue reactions, also known as deterministic effects,
are due to radiation effects on populations of cells and
are characterized by a threshold dose and an increase

in the severity of the reaction with increasing dose.7
These reactions are the primary concern for patients
undergoing FGI procedures, and will be the focus of this
report, with stochastic risks not being addressed. Tissue reactions do not occur at doses below a threshold
dose, which the International Commission on Radiological Protection (ICRP) defines as the dose estimated to
result in a 1% incidence of the tissue reaction.8 Tissue reactions in patients undergoing FGI procedures
may involve skin, hair, subcutaneous fat, muscle, the
lens of the eye, and sometimes bone.9,10 The generally accepted minimum threshold dose for transient skin
effects is an absorbed skin dose of approximately 2 Gy,
and permanent effects are unlikely below an absorbed
skin dose of 5 Gy.1,11 Risks for tissue reaction can
conservatively be assumed as cumulative when the
same skin area has been irradiated for other procedures. Repair of sublethal radiation injury to skin is typically complete within a day of exposure; repopulation
of cells can require months.11 Tissue reactions may
be expressed days to years after exposure, depending on the radiation dose and the tissue affected. Early
reactions may be due to inflammation, and may not be
noticed by the patient, whereas late reactions are typically due to cell loss. Tissue reactions in the skin range
in severity from erythema and transient epilation to dermal necrosis, which can require surgical intervention.12
Because of individual variability in radiosensitivity, the
radiation dose necessary to produce a specific effect
and the time course of the tissue reaction are best
thought of as ranges, rather than specific values, as
shown in Table 1, reprinted from Balter et al.11 Additionally, it should be noted that previously irradiated skin is at
a higher risk for developing tissue reactions than areas
that have had no prior exposure.

3

AVAILABLE DOSE INDICES

Predicting the likelihood of radiation-induced effects
from FGI procedures requires an estimation of the
patient’s radiation dose. Four measurable radiation dose
indices exist to assist with this estimation: fluoroscopy
time, cumulative air kerma (Ka,r or CAK), air kerma–area
product (PKA , also commonly written as KAP or dose–
area product/DAP), and peak skin dose (PSD). Effective
dose is not suitable for assessing the likelihood of tissue
effects. The availability and displayed units of each dose
index vary depending on equipment type, manufacturer,
and equipment age, and each differs in clinical utility and
application.
Fluoroscopy time is the most widely available index;
however, it is also the least useful in terms of predicting potential tissue effects. Fluoroscopy time alone is
inadequate to estimate patient dose. It does not consider fluoroscopic dose rate, and dose estimates that
rely solely on fluoroscopy time can vary widely, as
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Tissue reactions from single-delivery radiation dose to skin of the neck, torse, pelvis, buttocks, or arms

Band

Single-site
acute skin
dose range
(Gy)a

NCI skin
reaction
grade

A1

0–2

A2

Approximate time of onset of effects
Prompt
Early

Midterm

Long term

NA

No observable effects
expected

No observable effects
expected

No observable effects
expected

No observable effects
expected

2–5

1

Transient erythema

Epilation

Recovery from hair loss

No observable results
expected

B

5–10

1–2

Transient erythema

Erythema, epilation

Recovery; at higher
doses, prolonged
erythema; permanent
partial epilation

Recovery; at higher
doses, dermal atrophy
or induration

C

10–15

2–3

Transient erythema

Erythema, epilation;
possible dry or moist
desquamation;
recovery from
desquamation

Prolonged erythema;
permanent epilation

Telangiectasiab ; or
induration; skin likely to
be weak

D

>15

3–4

Erythema, epilation;
Transient erythema;
moist desquamation
after very high doses,
edema and acute
ulceration; long-term
surgical intervention
likely to be required

Dermal atrophy;
secondary ulceration
due to failure of moist
desquamation to heal;
surgical intervention
likely to be required; at
higher doses, dermal
necrosis, surgical
intervention likely to be
required

Telangiectasiab ; dermal
atrophy or induration;
possible late skin
breakdown; wound
might be persistent and
progress into a deeper
lesion; surgical
intervention likely to be
required

Note: Applicable to normal range of patient radiosensitivities in absence of mitigating or aggravating physical or clinical factors. Data do not apply to the skin or the
scalp. Dose and time bands are not rigid boundaries. Signs and symptoms are expected to appear earlier as skin dose increases. Prompt, <2 weeks; early, 2–8 weeks;
midterm, 6–52 weeks; long term, >40 weeks.
Abbreviations: NA, not applicable; NCI, National Cancer Institute.
a
Skin dose referes to actual skin dose (including backscatter). This quantity is not the reference point air kerma described by Food and Drug Administration (21 CFR
§ 1020.32 [2008]) or International Electrotechnical Commission. Skin dosimetry is unlikely to be more accurate than ±50%.
b
Refers to radiation-induced telangiectasia. Telangiectasia associated with area of initial moist desquamation or healing of ulceration may be present earlier.
Source: Reproduced from Balter et al.,11 Tissue reactions from radiation doses to the skin.

acquisitions (e.g., cine, Digital Subtraction Angiography
(DSA)), which can contribute substantial dose, are not
included in the measurement.13 If additional dose rate
and dose per image data are available for the specific
mode of operation used, using the number of fluorographic images from a procedure,along with fluoroscopy
time, can improve estimations of patient dose. However,
while fluoroscopy time is suboptimal for assessing radiation dose, it can be useful for other purposes (e.g., a surrogate for procedure complexity and comparing practice
among operators).
CAK (Ka,r ) is required to be displayed on all International Electrotechnical Commission (IEC) compliant
interventional fluoroscopes and all fluoroscopes sold
in the United States since June 2006.4,14,15 Ka,r is the
cumulative kerma for a fluoroscopic procedure,including
fluoroscopic and acquisition modes of operation, measured in air at a specific reference point relative to the
X-ray source. For isocentric C-arms, the IEC definition
for the reference point is along the central ray of the Xray beam, 15 cm from the isocenter toward the X-ray
tube, though manufacturers can use a different reference point if they choose. The specific reference point

used by a piece of equipment is defined in the operator’s manual. Ka,r is often used as a surrogate for the
patient’s PSD; however, potentially labor-intensive corrections and calculations are required if a more accurate
estimate of PSD is needed. These corrections include
backscatter, table and pad attenuation, displayed dose
index accuracy, and tissue-to-air ratio. Additionally, due
to beam geometry, gantry angulation, table height, and
patient size, the reference point may not coincide with
the entrance skin surface. This results in a tendency for
Ka,r to overestimate PSD. Despite these shortcomings,
Ka,r is generally considered a practical surrogate for skin
dose.2 Ka,r is almost universally reported in units of milligray (mGy) in modern fluoroscopes.
KAP (PKA ), sometimes called DAP, is the product
of air kerma and the geometric area irradiated in the
same plane orthogonal to the propagation of the X-ray
beam. PKA displays are widely available on interventional fluoroscopes and commonly available on many
modern mobile C-arms and conventional diagnostic fluoroscopy equipment. Unlike Ka,r , PKA is independent
of distance from the focal spot, because the irradiated
area increases proportionally to the decreased radiation
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intensity as distance increases. Therefore, small doses
to a large area and large doses to a small area could
give equal PKA values. For this reason, PKA is considered a poor indicator of skin dose and radiation-induced
tissue effects. Because PKA represents the total energy
deposited in the patient,it is better correlated to stochastic risk as compared with Ka,r . Additionally, a lack of
standardized units for displayed PKA values on fluoroscopic equipment can make the practical implementation of clinical thresholds difficult. PKA displayed units of
uGy × m2 , mGy × cm2 , cGy × cm2 , and Gy × cm2 are
all in use.
PSD indicators, with real-time dose mapping displays,
are the least common dose index available at present
but are becoming increasingly common on modern FGI
equipment. They allow the operator to visualize the
three-dimensional skin dose distribution, potentially preventing tissue reactions. Freestanding software, independent of the FGI equipment, is also available that
can estimate PSD based on data provided in the radiation dose structured report (RDSR). Real-time PSD
information provides the greatest clinical utility for predicting the likelihood of tissue reactions because it provides estimates of the highest skin dose and its location using information on patient position,X-ray field size,
and beam angulation during a procedure. Freestanding
software that reconstructs PSD from RDSR information
also has clinical utility but lacks direct feedback to the
operator during a procedure. It is important to be aware
of manufacturer-specific approaches to PSD estimates
and their level of sophistication with regard to inclusion
of correction factors such as backscatter, table and table
pad attenuation, and patient anatomical representation.
Because of these differences in approach, it is possible that fluoroscopes from different manufacturers, or
even different versions of the same manufacturer’s software, could provide different PSD values given identical
RDSRs. A review of various PSD software options was
presented by Malchair et al.16 At present, real-time PSD
estimates are limited to FGI fluoroscopes and are not
found on mobile C-arms or general fluoroscopic equipment. PSD is commonly reported in units of milligray
(mGy).
In setting up a patient fluoroscopy dose management
program, the QMP will need to survey the dose indices
available on the imaging equipment in a facility or larger
healthcare system. The availability of these indices will
determine the dose index used to set thresholds for further action. Some dose indices may be available but
require equipment configuration in order to be displayed.
For older equipment that does not display Ka,r or PKA ,
aftermarket meters can provide this capability. Ideally,
one would use PSD, the dose index that best correlates
with potential tissue injury, but its limited availability and
the variability in assumptions and corrections made by
PSD algorithms complicate its use at the present time.
Due to its standard definition, ubiquitous implementa-
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tion, and reasonable correlation with PSD, it is the recommendation of this group that CAK (Ka,r ) be the primary dose index used in setting fluoroscopic threshold
dose levels for notification and patient follow-up.

4

FGI POLICY

The following sections broadly describe the policies that
facilities must have in place, regardless of regulatory
or accreditation requirements, to increase stakeholder
awareness and to help prevent, identify, and properly
care for patients with tissue reactions due to high-dose
FGI procedures. These policies are broken into three
sections:
1. Pre-procedure screening and consent of the patient.
2. Intra-procedure monitoring and notification of patient
dose index level to the team.
3. Post-procedural patient follow-up above threshold
levels.
While QMPs are not typically involved in the day-today implementation of these policies and procedures,
their expertise is critical in development of the policies.
Additionally, the QMP can be consulted when specific
questions arise and may be called upon for PSD or other
dose estimates.

4.1
Pre-procedure consent for risk of
skin injury
Each healthcare facility must create a policy for obtaining a radiation-specific consent from patients prior to
FGI procedures where patients are given information
regarding the risks of radiogenic tissue effects. Whenever possible, this policy should be standardized across
all departments utilizing FGI equipment across the
entire organization. Local laws may dictate whether consent can be verbal or must be written. A facility may
choose to obtain this consent before all procedures performed in FGI suites or only before a subset of procedures classified as potentially high dose. The QMP can
aid in reviewing facility data to determine which procedures require consent. NCRP Report No. 168 suggests classifying procedures as “potentially high radiation dose procedures” if more than 5% of procedures
result in Ka,r exceeding 3 Gy.1 Obtaining a radiation consent for only a subset of procedures removes a clinical
step prior to procedures where tissue effects are highly
unlikely. However, it may complicate policy and process
by requiring someone to create and keep updated a list
of procedures in radiology, cardiology, surgery, and other
specialties requiring radiation consent.
An example of simple radiation consent language,
adapted from the SIR’s guidelines for patient dose
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management, can be found in Appendix A.17 Additional example consent language can be found in NCRP
Report Nos.168 and 185.1,18 Any such document should
be reviewed by appropriate clinical and legal teams prior
to implementation. Key elements of consent language
should include a description of the use of X-rays in fluoroscopy, the possible tissue effects resulting from prolonged exposure to X-rays, the typical time delays for
these effects to occur, and the proposed action(s) for the
patient and/or caregiver if any effect is observed.

4.2

Pre-procedure screening

In addition to screening for potential medical issues or
pregnancy, patients who will undergo potentially highdose FGI procedures should be screened to determine if they are at higher risk for tissue effects. The
result of pre-procedure patient screening is then conveyed to the performing physician. Patients at higher
risk include those who have had recent high-dose fluoroscopy procedures or a history of radiation therapy to
the same skin area, collagen vascular disease, or certain genetic disorders that affect DNA repair, which are
further detailed in Ref.11 High body mass index (BMI)
is also a risk factor since the greater amount of tissue
increases the amount of radiation needed to yield an
adequate image and can result in the skin being closer
to the X-ray source.19

4.3
Intra-procedure monitoring and
notifications
Intra-procedural notifications regarding radiation dose
levels allow the performing physician to gauge the
benefit–risk ratio at each stage of an FGI procedure.
All FGI procedures should be justified, that is, offer a
clinical benefit to the patient greater than the potential risks, which include radiation tissue reactions.1 This
benefit–risk ratio is considered by the physician when
initially deciding whether to perform a procedure, and
later, while the procedure is in progress. For the benefit–
risk ratio to be meaningful, the physician needs to have
an accurate understanding of radiation risk, the likelihood of tissue injury, and the associated dose–response
relationship.11 The QMP, as the subject matter expert
in this area, can provide radiation protection planning
knowledge to the team to help ensure that the benefit–
risk ratio is formulated correctly. The QMP must also
understand the magnitude of radiation risk compared
to other procedural risks, which are often much greater
than the risk of tissue reaction. The risk of a radiation
effect is typically much smaller than other procedural
risks, such as bleeding, infection, and organ damage.
However, the benefit–risk ratio is not static, and may
change during the procedure. This analysis should be
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performed by a well-informed operator and should be
evaluated throughout the procedure. Procedures should
rarely, if ever, be stopped solely due to radiation dose. If
all or most progress made during the procedure is lost if
the procedure is stopped (e.g., navigation of catheter to
a very difficult site, or risk of developing collateral vasculature in the interval), any risks already incurred will have
been for no benefit to the patient.1 When appropriate
clinically, very complex procedures may be planned in a
staged fashion, with multiple sessions separated by 8–
10 weeks, to fractionate the dose to the skin and reduce
the likelihood of tissue reactions.
The concept and implementation of radiation dose
notification levels is simple. The same concept has been
applied to other potentially toxic agents, such as iodine
contrast or medications.1 The implementation of notification levels requires the entire procedure team to work
together. For example, the radiologic technologist, who
is a local expert on the operation of fluoroscopy equipment, may be the one who calls out when the notification
level is reached and documents this action in the procedure record. The nurse may then document the same
information in the electronic medical record, while the
operator or performing physician pauses for a moment
to consider their radiation management strategy and the
current benefit–risk pace of the procedure.
The essential elements of an intra-procedural dose
notification are:
1. Verbal notification to the operator regarding the current notification number and the magnitude of the
dose index, for example, “This is the third notification.
The current reference air kerma is 5000 mGy.”
2. Consideration of a procedural pause to evaluate
setup and the benefit–risk pace of the procedure, if
such a pause will not interfere with the conduct of the
procedure.
3. Documentation of the notification level, that the operator was notified, that the setup and benefit–risk ratio
of the procedure were evaluated, and any specific
actions taken by the operator.
The notification should be delivered during a natural pause during the procedure, if possible, and should
never interrupt a critical phase of the procedure. Reconsideration of radiation dose management strategy
after a notification may include specific actions including, but not limited to:
1. Adjustment of the patient table height. Sometimes it
is set within the optimal range at the beginning of the
procedure, but may be lowered during the procedure,
for example, to isocenter the patient for volumetric
imaging, after which the table is not moved back to
the original height.
2. Elimination of a large air gap by lowering the image
receptor.
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3. Evaluation of X-ray beam collimation and gantry
angle.
4. Evaluation of currently selected organ program (aka
imaging protocol) for aspects such as dose rate setting, pulse rates, and DSA frame rate.
Traditional radiation management practice often suggests that the angle of the gantry be varied during a procedure to “spread” radiation dose across the skin. While
this strategy can be useful in specific circumstances as
a prophylactic technique, it can be detrimental to radiation management and greatly increase both the skin
dose rate and the PSD, especially in cases where larger
oblique angles both increase radiation output and put
the patient’s skin surface closer to the tube.20–22 If used
as a radiation management strategy, tight collimation of
the X-ray beam increases the benefit of this technique.20
Onboard, real-time PSD mapping capabilities, if available, can help determine the benefit of these strategies.
Until a time at which PSD is widely available as a realtime displayed dose index, Ka,r is the preferred dose
index for dose notifications in fluoroscopy. However, as
PSD is more closely correlated with the likelihood of tissue reaction, it should be used for intra-procedural notifications when available. Conservatively, values for both
planes in biplane procedures should be summed for the
purpose of intra-procedural notifications.1 Multiple publications exist with a consensus recommendation for setting notification levels with the first notification at 3 Gy
Ka,r and subsequent notifications every 1 Gy Ka,r .1–4,17
However, there are practice-specific considerations for
setting notification levels, as well as patient-specific considerations, such as the presence of sensitizing factors,
that should be used to modify notification values when
appropriate. Practice-specific factors to consider when
setting notification levels include:
1. Types of procedures performed: Depending on the
procedure type (e.g., neuro, body, cardiac) the fluoroscopy dose notification level could be adjusted in
consideration of the relationship between Ka,r and
PSD. The geometry of the procedure affects the
ratio of PSD to Ka,r , denoted as the “dose index” by
Miller et al.4 To avoid confusion, the “dose index” as
described by Miller,will be referred to as the “PSD factor” in this report. For non-isocentric procedures, such
as those performed in vascular and interventional
radiology, the PSD is often similar to the reported
Ka,r (PSD factor ∼ 1.0).23 For isocentric procedures,
where the relevant anatomy is placed at isocenter to
facilitate the use of multiple gantry angles, the skin
dose will be higher than the Ka,r if only a single projection,or a narrow range of projections,is used (PSD
factor > 1.0). However, isocentric procedures often
require the use of many different gantry angles,which
may result in multiple distinct “fields”on the skin of the
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patient. This tends to reduce the dose index, and the
PSD would be less than the Ka,r (PSD factor < 1.0).
2. Equipment capabilities: Many interventional fluoroscopes now offer the capability to program one or
more fluoroscopy dose notification levels into the system. Upon reaching that notification level, an alarm
sounds and/or a visual indication is displayed at the
position of the operator. If, for example, a fluoroscope
offers only three such levels at fixed values, this is
a consideration when selecting the first, second, and
third notification levels in policy. Different notification levels may be implemented for different services
based on the type of procedures performed or the
available dose indices. The QMP should ensure that
any programmed dose notification levels are harmonized, though this can be complicated by differences
in manufacturer’s specific alert configurations.
3. Alarm fatigue: The 5-min fluoroscopy timer is often
ignored in interventional fluoroscopy because it
sounds numerous times during most procedures.
Avoiding similar alarm fatigue with dose notification
levels is an important consideration,both for the value
of the first notification level and the intervals between
notification levels.
One other important intra-procedural notification is
the rapid recognition and correction of unsafe conditions when they exist. Examples of unsafe conditions
include the presence of the patient’s arm in the field
of view when the arm is not the area of interest, and
direct irradiation of the eye lens or female breast tissue
when unnecessary.24 Every member of the procedural
team should be confident in identifying such conditions
when they exist and reporting them to the operator and
responsible physician.
Diagnostic medical physicists can provide maximum value to their healthcare organizations only when
they understand the clinical aspects of fluoroscopically
guided procedures. Fluoroscopy dose indices can only
be understood completely when accompanied by the
clinical context of the procedure, and imaging protocols
for fluoroscopy can be optimized only when the tasks
involved in completing the procedure are understood.
For these reasons, it is important that a QMP who supports a clinical FGI practice be provided clinical instruction and time to observe clinical procedures, including
how the equipment and protocols are used by physician
operators. It is likely that this observation time can also
be used to optimize protocols.

4.4
Establishing the SRDL and
post-procedure actions
The substantial radiation dose level (SRDL) is an
operational threshold for radiation dose above which
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additional post-procedure actions for patient care
should be taken due to the potential for biological
harm. The SRDL should be set to a level such that a
radiation dose below the SRDL is unlikely to result in
a tissue injury for an average patient of normal radiation sensitivity. However, “there is no implication that a
radiation level below an SRDL is absolutely safe or that
a radiation level above an SRDL will always cause an
injury,” and patient-specific factors such as underlying
conditions or medications could influence the threshold
to induce a tissue reaction.1 Suggested values for the
SRDL are 5 Gy Ka,r or 3 Gy PSD.1,17,19 Since real-time
PSD estimates are not typically available on most
equipment, use of Ka,r is generally recommended to
establish thresholds for post-procedure follow-up.
When setting the Ka,r SRDL value, the previously discussed PSD factor concept should be considered.25 If
it is known that the entrance skin point is likely to be
unchanged during a procedure or the skin is closer to
the X-ray source than the interventional reference point
(IRP)/patient entrance reference point (PERP), a lower
SRDL may be warranted.14 Similarly, for biplane procedures, the dose received from each plane should be
added for SRDL purposes unless it is known that the
fields do not overlap.
Each facility must have a policy for identifying patients
who receive a radiation dose exceeding the SRDL
and for providing patient management and follow-up,
including provision of post-procedure information written in simple language. This document (see Appendix
B, adapted from NCRP Report No. 168 language, for an
example) should provide educational information about
the procedure, follow-up information, and provider contact information for questions or concerns. This information can be provided in discharge instructions, in the
electronic medical record, or both. Determination of the
individual responsible for distributing these instructions
is vital and should be part of the facility’s policy. Technologists,nurses,physicians,or physician assistants can
be assigned this duty. Further, the facility must have an
established system for patient follow-up and must document any such communication in the medical record.
Follow-up may be in-person or via telemedicine and
may reasonably be provided by any trained clinical team
member, under the direction of the performing physician. All tissue effects should be assumed radiogenic
until proven otherwise. If a severe or prolonged radiogenic tissue reaction is observed, the patient should be
seen in person by the performing physician whenever
possible and referred to dermatology, wound care, radiation oncology, or another appropriate specialty for further care, with all appropriate information included in the
patient’s medical record.
PSD estimates may be useful for patient management
in some cases. Facilities should have a defined process
for requesting a PSD estimate performed by or under
the supervision of a QMP. PSD estimates required by
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policy, regulation or accreditation standard, or requested
from a licensed provider, must be documented in the
patient medical record. The details of estimating PSD
from dose indices are outside the scope of this document and have been described elsewhere.26,27 Due
to the various assumptions and inherent uncertainties
involved, PSD estimates are unlikely to be better than
±50% accurate.11 This uncertainty should be included
in any estimate and QMPs should always include a
range of possible values in addition to the likely PSD
value. For example, depending on various assumptions
made regarding variable procedure aspects such as
table height, collimation, and beam angulation, a PSD
estimate could be documented as “likely 13 Gy, but with
a probable range of 8–18 Gy.” As of January 2021,
the American Medical Association (AMA) added a billable Current Procedural Terminology (CPT) code that
refers to PSD estimates; code 76145 applies to evaluation of radiation exposure that exceeds institutional
thresholds.28

4.5
Cumulative doses and risk of
tissue reactions
There may be instances where a patient has multiple
procedures in a short span of time where no single procedure reaches the threshold for patient follow-up, but
the summed doses warrant action. Setting an appropriate time window for a meaningful summation of doses is
challenging.As previously mentioned,repair of sublethal
radiation injury to skin is typically complete within a day
of exposure, so doses delivered within a 24-h period
should invariably be summed. However, repopulation of
damaged cells can require months. The SIR’s guidelines
for patient dose management suggest summing doses
over a 60-day period,while prior TJC sentinel event standards required summing doses over 6–12 months.4,17,29
This report recommends 60 days as the most biologically meaningful time window for summing patient skin
dose. The same thresholds for follow-up should be used
for single or multiple cumulative procedures that exceed
the SRDL.
Identifying patients with high doses from multiple procedures, and their potential risk, is technically challenging. The patient’s history of radiation exposures may be
incomplete if some exposures occurred at outside facilities, or even in a different department within the same
facility, if procedure information is not shared. Even with
sophisticated dose management software that can track
patient dose, there can be a time lag in identifying these
patients, who may be discharged before they are identified as having exceeded SRDLs. In these cases, facility
policy should identify how the patient will be contacted
and who will be responsible for follow-up. The treating
physician is ultimately responsible for ensuring followup is performed.
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5
SPECIAL CONSIDERATION FOR
PEDIATRIC AND PREGNANT
PATIENTS—QMP INVOLVEMENT IN RISK
ASSESSMENT
As previously described, QMPs are generally the most
knowledgeable individuals on radiation risk and play an
important role in the fluoroscopic dose management
process. This knowledge is critical in cases of pediatric
or pregnant patients undergoing fluoroscopic procedures, as both can be at higher risk of radiation effects.
On average, both the pediatric patient and the fetus
are at higher risk for stochastic effects from radiation
exposure due to more rapid cell growth and a comparatively greater number of undifferentiated cells compared
with adults, as well as their longer remaining expected
lifespan.30 In addition to these risks, each has the possibility of unique tissue reactions. Pediatric patients have
shown a lower threshold for cataract development.10
High fetal doses during particular stages of development can result in loss of pregnancy, fetal organ malformation, or intellectual disability.31 In addition to the dose
estimation roles discussed below, for both pediatric and
pregnant patients, the QMP can play a role by providing
direct counseling to the patient or guardian in order to
provide information and address any potential radiation
concerns.
The principal role of the QMP in pediatric fluoroscopy
should be dose management in patients, ensuring that
the radiation dose is no greater than necessary to maintain image quality adequate for the clinical task. QMPs
should ensure that clinical staff are aware of the magnitude of the radiation risks involved and any thresholds for effects. The QMP must consult with clinical
teams to ensure that appropriate fluoroscopic equipment is used and protocols are optimized for pediatric patients. This is particularly important, as patients
can range in size from premature infants weighing less
than 1 pound to adolescents who exceed normal adult
dimensions. Examples of protocol elements that the
QMP should consider, when appropriate, for pediatric
fluoroscopy are:
1.
2.
3.
4.
5.

Reduced pulse rate or width.
Reduced tube current.
Use of small focal spots for higher resolution imaging.
Removal of the anti-scatter grid in smaller patients.
Selection of appropriate image-processing parameters.
6. Selection of any other appropriate patient dose
reduction controls.
Operators should be mindful of routine methods for
dose reduction, such as proper attention to collimation, magnification, pulse rate, and source-to-skin and

FISHER ET AL.

source-to-image-receptor distance. Regular use of preprocedure checklists, such as the one provided by
Image Gently, can help the QMP operationalize these
behaviors.32
For fluoroscopy of a pregnant patient and fetus, the
QMP plays a similar role. There may also be instances
in which FGI procedures are performed on a woman
with an unknown pregnancy. In these cases, the QMP
will often be involved in estimating fetal dose. Details of
fetal dose estimate methods can be found in Wagner
et al.31
When fluoroscopic imaging is necessary on a known
pregnant patient, clinicians should consult with the QMP
to estimate the radiation dose and potential risk to the
fetus. Procedure planning should include a consideration of imaging protocol optimization, collimation, and
the relationship between fetal dose and displayed dose
indices. Additionally, the QMP may be asked to be available during the procedure for consultation and to make
sure adequate information is obtained for a fetal dose
estimate. More specific fetal dose estimates can be
obtained with the use of thermoluminescent dosimeter
(TLDs) or Optically stimulated luminescence dosimeter
(OSLDs), as described in Dauer et al.33 With appropriate
preparation, complex interventional procedures in the
abdomen and pelvis, such as renal or trauma embolizations, can often be completed with relatively low fetal
doses.

6
FLUOROSCOPIC EQUIPMENT
EVALUATIONS
Certain aspects of acceptance testing, commissioning, and periodic acceptability testing of fluoroscopy
systems deal with patient and staff radiation dose
management.24 Such aspects include, but are not limited to, scatter survey and comparison to manufacturerprovided isokerma plots, measurement of table and pad
transmission factors, measurement of typical and maximum air kerma rates for fluoroscopy and acquisition
modes of operation, imaging protocol design and review,
and measurement of the accuracy of machine-reported
dose indices. Accreditation and regulatory requirements may require additional tests and establish minimum standards and frequencies for such evaluations.34
AAPM Task Group reports, Medical Physics Practice
Guidelines (MPPG), and American College of Radiology (ACR) Practice Parameters may provide guidance on test methods, expected values, and the role
of the QMP and other personnel in performing these
evaluations.35–39 It is also important to establish performance baselines during acceptance testing, compare
these baselines to manufacturer specifications, where
applicable, and to compare future measurement values
to established baselines.
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7
THE JOINT COMMISSION
FLUOROSCOPY REQUIREMENTS
TJC, a healthcare accrediting body in the United States,
has instituted standards on the use of fluoroscopy
and on the management of radiation exposures to
the patients of accredited facilities. Effective 1 January
2019, healthcare organizations accredited by TJC are
required to meet new “elements of performance” related
to fluoroscopy, including annual equipment performance
evaluations, documentation of procedure dose indices,
setting SRDLs, and review of procedures exceeding
the SRDL.34,40–43 These requirements are in addition
to TJC’s updated fluoroscopy sentinel event, which
requires root cause analysis review if permanent tissue injury results from improperly performed procedures.. The QMP is an integral part of the healthcare team tasked with meeting these requirements.
TJC rescinded pre-publication standards that specifically required annual radiation dose optimization training for fluoroscopy operators.

7.1

Annual equipment evaluation

TJC standards (Element of Performance No. 34,
EC.02.04.03) state that at least annually a diagnostic
medical physicist must conduct a performance evaluation of all fluoroscopic imaging equipment. This requirement excludes equipment used for therapeutic radiation
treatment planning or delivery, but includes FGI suites,
over- and under-table fluoroscopy rooms, and mobile
and mini C-arm fluoroscopes.34 AAPM MPPG 10a suggests that all fluoroscopic performance evaluations be
performed by a QMP, though according to TJC, they may
be assisted by individuals with the required skills, as
determined by the QMP.34,37

7.2

Dose index documentation

TJC standard (Element of Performance #30,
PC.02.01.01) states, “The reference-air kerma,
cumulative-air kerma, or kerma-area product are [sic]
documented in a retrievable format … such as a picture
archiving and communication system.” (Note that “reference air kerma” and “CAK” are two terms for the same
dose index: Ka,r .)41 If a system does not display the
CAK or KAP, the fluoroscopy time, mode of operation,
and number of images should be documented instead,
in a retrievable format. According to a clarification from
TJC in January 2019, this element of performance
does not apply to fluoroscopy equipment used for
therapeutic radiation treatment planning or fluoroscopy
equipment classified as a mini C-arm. Documentation
is still required for other non-FGI fluoroscopes such
as full-sized mobile C-arms, remote, and tableside
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fluoroscopy systems, despite the fact that there can
be considerable cost involved in implementing such a
system and questionable benefit as the entrance skin
dose resulting from these systems are typically very low.
A facility’s choice of method for documenting fluoroscopy dose indices depends on the equipment in use,
the size of the healthcare system,and the resources and
technology available. Possible solutions include:
1. Archival of fluoroscope produced dose information
into picture archiving and communication system
(PACS).
2. Manual logs.
3. Manual entry into permanent patient records, such as
patient electronic medical records (EMR), the PACS,
and hospital or radiology information systems (HIS
and RIS).
4. Automatic radiation dose index monitoring software.
The QMP, as a subject matter expert, is often
involved in helping facilities comply with these requirements. These solutions require a collaborative approach
between medical physics and hospital Information Technology (IT) and/or PACS administrators,and each facility
needs to determine which approach is best, based on
the capabilities of their equipment and available technology.
One solution to documenting dose index data is to rely
on RDSRs and dose summary pages produced by the
modality, which are often sent to PACS along with any
procedure images. While this approach is appealing in
that it is simple and requires no additional software systems or manual recording of data,it has several potential
disadvantages. Procedure dose summaries and RDSRs
are common on modern FGI equipment, but legacy, general, or mobile fluoroscopes might not produce them,
necessitating additional documentation methods. The
dose summary approach can also result in fragmented
storage locations, as dose data reside within individual patient PACS records instead of a central location.
Often, various hospital services utilize entirely separate PACS systems, which can further complicate data
retrieval. Storage of dose index data in multiple locations can hinder the ability to aggregate dose indices
from multiple procedures or to do facility dataset review
for quality improvement purposes as discussed later in
this report.
Paper logs are the simplest and least expensive to
implement and meet the recommendations but present
possible Health Insurance Portability and Accountability
Act (HIPAA) issues due to protected health information
(PHI) required for retrieval, as well as potential accuracy
and legibility issues common to manual records. Additionally, paper records, if used, do not lend themselves
easily to data analysis. Having dose index, equipment,
and operator information in a digital format makes it
possible to better evaluate dose indices and equipment
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use, in addition to allowing easier auditing of operators’ habits. For these reasons, this MPPG recommends
paper logs be used for fluoroscopy dose index tracking
only when digital formats are not possible. Manual entry
into digital formats, such as spreadsheets, can avoid
some potential HIPAA issues and can be better used for
data analysis, but may still suffer accuracy issues from
manual entry.
Fluoroscopy procedure information entered into digital formats has the advantage of being inherently electronic and can often be directly linked to sources such as
HIS,RIS,or HL7 feeds,which can automatically populate
patient information with high fidelity. This method also
avoids potential HIPAA issues, as these systems are
generally much more secure than physical notebooks or
spreadsheets stored on network drives. Reports including patient and procedure information, equipment operator, and dose indices can be easily generated from
these data, which can be useful for auditing and analysis, though manual entry can lead to data errors and
false alarms. Specific methods of data entry can vary.
Since fluoroscopy equipment is often operated outside
of radiology departments, access to software systems
should be considered. Data entry into systems such as a
RIS may not be possible in hospital departments outside
of Radiology, possibly necessitating multiple avenues of
data entry for a centralized dose index database. The
QMP will likely need to work closely with hospital IT
and/or PACS administrators in order to set up such a
system.
Automatic radiation dose index monitoring systems
can eliminate most manual entry and automatically populate a database with patient and dose index information, greatly increasing data fidelity. This functionality is
dependent on the fluoroscopy equipment in use. While
most new FGI equipment can produce RDSRs that are
sent directly from the modality, much of the fluoroscopy
equipment used today does not support RDSR functionality and may not be integrated easily into commercial
radiation dose index monitoring systems. Specifically,
it may be difficult to get dose information from legacy
equipment, R/F rooms, and mobile or mini C-arms into
these systems, necessitating a separate documentation
system for those data. An additional challenge is connectivity between dose index monitoring systems and
patient electronic medical records, leading to lack of
access to patient dose data for referring physicians or
interventionalists who perform FGI procedures. Better
integration of these systems would improve patient care
by providing immediately available radiation dose information to physicians.
Regardless of the specific method for storage, regular
monitoring and maintenance of the radiation dose index
database is critical to its long-term success. New staff,
new devices, and software upgrades have the potential
to disrupt the methods used to document radiation dose
indices. Even without changes to the hospital workflow,
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missing or incomplete data are possible. Regular system monitoring and maintenance allows for adjustments
as needed to ensure that the quality of radiation dose
data is maintained and documented.Again,the QMP is a
likely candidate for this task, though time should be allocated for this work, which can take considerable effort.
Most facilities will adopt an iterative approach and continue to improve their data capture process over time.

7.3
Identification of radiation exposure
thresholds
TJC standard (Element of Performance #30,
PC.02.01.01) requires a facility to “identify radiation exposure and skin dose threshold levels, that if
exceeded, trigger further review and/or patient evaluation to assess for adverse radiation effects.”42 TJC
does not provide any specific recommendations for
threshold levels but does refer to NCRP Report No. 168.
Prior discussion of SRDLs in this document addresses
recommendations for complying with this standard.
The QMP should be involved in setting these threshold
levels and drafting policies.

7.4
Reviewing and analyzing
procedures over threshold
TJC standard (Element of Performance #20,
PI.02.01.01) requires that the organization providing fluoroscopy services “review and analyze instances
where the radiation exposure and skin dose threshold
levels identified by the organization are exceeded.”43
TJC does not limit this threshold review to FGI procedures but includes all fluoroscopic services. TJC
does not specify how this review and analysis is to be
accomplished, only that it be done. Previous discussion
in this document regarding appropriate patient follow-up
for procedures above the SRDL is presumed to be sufficient. For policy purposes, the prior recommendations
in this document may be followed with the FGI SRDL
applied to lower dose fluoroscopic equipment as well
(mobile C-arm fluoroscopic units for use in operating
rooms, general fluoroscopic units used for low-dose
diagnostic studies, etc.). Procedures completed with
this equipment typically have very low Ka,r and it is
unlikely that any non-interventional procedure will have
a Ka,r above the SRDL.

7.5

Sentinel event requirement

TJC adopted a sentinel event policy in 1996 for monitoring patient safety events that lead to death, permanent
harm, or severe temporary harm, and that are not
related to the natural course of a patient’s underlying
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illness or condition.44 In 2005, TJC added “radiation
overdose” as a reviewable sentinel event, which, in addition to the delivery of radiotherapy to the wrong region
or >25% above the planned dose, included “Prolonged
fluoroscopy with cumulative dose >1500 rads [15 Gy]
to a single field.”29 In a subsequent publication, the TJC
clarified that monitoring cumulative fluoroscopy PSD
over a period of 6 months to 1 year would be reasonable, ultimately leaving the decision of determining the
cumulative dose monitoring time window to the accredited institution.29 If a sentinel event occurs, TJC requires
conducting a comprehensive systematic analysis, identifying causal and contributory factors, and documenting
a corrective action plan, as well as a recommendation
(but not requirement) to report the event to TJC.44 The
most common approach to this analysis is a Root Cause
Analysis (RCA), which needs to be completed within
45 days of becoming aware of the event. Additionally,
in order to be considered a credible analysis, the RCA
is required to include senior healthcare organization
leadership.44
Practical implementation of the “radiation overdose”
sentinel event has been difficult. Compliance required
knowledge of PSD, an index not widely available on
fluoroscopic equipment. For the majority of fluoroscopy
systems that do not report PSD, estimations of patient
and procedure-specific PSD are laborious and prone
to uncertainty. Even with all information available, skin
dosimetry estimates are unlikely to be more accurate
than ±50%.11 Due to PSD uncertainty and variation
in individual radiosensitivity,44 it is possible for patients
to develop severe tissue reactions at estimated PSDs
below the 15 Gy sentinel event definition. Conversely, it
is possible for patients with estimated PSD greater than
15 Gy to experience no tissue effects.
The “radiation overdose” fluoroscopy sentinel event
was unique among TJC sentinel events. Other sentinel
events include patient suicide, abduction, or elopement
leading to death or serious harm, unanticipated death
of an infant, discharge of an infant to the wrong family,
wrong site or patient surgeries or radiotherapy,or assault
or homicide of patients or staff.44 All of these can reasonably be described as preventable events that should
never occur in the normal provision of healthcare services. While high radiation tissue doses can result in
temporary or permanent harm, a PSD exceeding 15 Gy
does not necessarily indicate that standards of care
were not upheld. Some complicated FGI procedures
require very large radiation skin doses to complete, even
when justified and optimized. There is also wide variation in patient size and lesion characteristics for some
FGI procedures,which may result in wide ranges of PSD.
This is not to say that high skin doses should not be
investigated, or that it is not possible that severe tissue
reactions could, in some cases, have been avoided by
better practice. However, investigating a “radiation overdose” sentinel event often led to large expenditures of
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time and resources in pursuit of RCA of properly performed procedures, and potentially excluded investigation of serious tissue reactions that occurred at a PSD
below the rigidly defined PSD threshold.
Due to these limitations, TJC made changes to the
fluoroscopy sentinel event requirements in 2021, with
changes going into effect in January 2022. The updated
requirement now defines a sentinel event as “Fluoroscopy resulting in permanent tissue injury when clinical and technical optimization were not implemented
and/or recognized practice parameters were not followed.”

8
THE NCRP STATEMENT 11
PROCESS
NCRP Statement No. 11 provides an administrative process for facilities to manage certain adverse events from
FGI procedures in line with the new TJC sentinel event
definition, which triggers a review based on identified
tissue reactions rather than a PSD threshold.45 Since
tissue reactions can occur at PSD below the previous
15 Gy threshold, the Statement No. 11 process factors
in an individual patient’s radiosensitivity and applies to
procedures that would not previously rise to the level of
a sentinel event. By focusing on patient outcomes rather
than PSD thresholds, the NCRP process also avoids the
ambiguous time frame for multi-procedure dose accumulation in the TJC’s previous sentinel event definition.
It also eliminates any ambiguity as to whether an estimated PSD value with large uncertainty requires a full
RCA.
NCRP Statement No. 11 recommends that facilities develop a quality assurance and peer-review (QAPR) program. This program promotes radiation management by tracking and reviewing available radiation
dose indices periodically and triggering patient follow-up
when specified threshold values are exceeded, as previously discussed in this document. The program includes
a QA-PR committee, which evaluates radiation management for FGI procedures based on clinical and dosimetric data. This committee is composed of a QMP and professional practitioners so that it is competent to evaluate the clinical appropriateness and relevance of quality
and safety matters. This committee would then suggest
and implement corrective actions as needed.
In instances where patient follow-up results in a suspected clinically important radiogenic tissue reaction,
this QA-PR committee would evaluate the procedure,
including clinical and dosimetric data, to determine if it
met recognized practice parameters, using the following
criteria, where applicable:
1. Clinical justification of the procedure.
2. Proper pre-procedural review and evaluation of the
patient’s past FGI encounters for skin injury.
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3. Proper discussion of the potential for tissue reactions
during informed consent process.
4. Appropriate use of radiation during the procedure.
5. Appropriate post-procedure patient follow-up.

some states as regulations. The following discussion is
based on Part F of the SSRs “Medical Diagnostic and
Interventional X-ray and Imaging Systems.”47

According to the NCRP, the possible outcomes of the
QA-PR evaluation are:

9.1

1. The tissue reaction was detected through follow-up
and likely unavoidable. No action required.
2. Clinical or technical optimization might have reduced
the severity or improved in the detection of the reaction, but overall practice criteria were met. Methods
for optimization should be implemented.
3. Radiation use did not meet recognized practice
parameters. A clinically important tissue reaction was
potentially avoidable, its severity could have been
minimized, or it was not detected. Corrective action
is required.
Statement No. 11 recommends that an RCA be
undertaken only in the last case, if one or more practice
parameter criteria were not met. This initial QA-PR
review eliminates the need for a full RCA with executive administration involvement for procedures where
appropriate clinical care was provided.
The initial goals of TJC’s “radiation overdose” sentinel event were proper identification and follow-up of
patients with the potential for tissue effects,and the identification of instances where high tissue doses were not
justified. It is the opinion of this group that these goals
are better accomplished under the new sentinel event
requirement and by following the recommendations of
NCRP Statement No. 11, which makes better use of
clinical resources to address TJC’s concern of undiagnosed radiation-induced tissue effects. Under this system,a PSD calculation by a QMP is only needed to direct
proper dermatological care in cases of a known severe
reaction, or as required by the facility’s established process for PSD evaluation. Radiation fields should be
assumed to be overlapping unless evidence suggests
otherwise. Readers are again referred to Jones and
Pasciak26 and AAPM TG 357 for more detailed discussion of performing PSD estimates.27 In cases where
radiation use did not meet recognized practice parameters, an RCA, including the QMP and members of hospital executive administration, must be performed as
described by TJC.46

9

SUGGESTED STATE REGULATIONS

The CRCPD maintains guidance that states may use
when drafting regulations regarding the safe use of ionizing radiation through its Suggested State Regulations
for Control of Radiation (SSRCR, or more commonly,
SSR). The SSRs are adopted without modification by

Radiation Protocol Committee

The SSRs recommend the creation of a Radiation Protocol Committee (RPC) responsible for ensuring “that
exams being performed achieve the desired diagnostic image quality at the lowest radiation dose possible
while properly exploiting the capabilities of the equipment being used.”
The SSRs state that the RPC includes, at a minimum,
a supervising physician, a QMP, and a lead technologist.
This MPPG recommends the following specific responsibilities for each of these individuals:
1. Supervising physician: The supervising physician, a
physician who performs FGI procedures, has the
responsibility for overseeing the activities of the RPC.
This physician also works with the lead technologist to develop and maintain imaging protocols. When
necessary, this physician serves as the liaison to
other physicians for issues related to patient safety,
such as long fluoroscopy times compared to peers.
2. QMP: The QMP brings a knowledge of radiation
safety and dosimetry to the RPC.The QMP is responsible for testing, or overseeing testing, of the FGI
equipment to ensure it operates safely. The QMP
also provides PSD estimates when necessary and
advises on the impact of the administered radiation
dose on the patient.
3. Lead technologist: The lead technologist is responsible for maintaining imaging protocols under the
direction of the supervising physician and QMP. This
technologist advises the other RPC members of
equipment issues or other observations that may
affect patient dose or image quality. When PSD
estimates are required, the lead technologist assists
the QMP in gathering the necessary data.
The organizational structure of the healthcare system
will dictate the optimal committee arrangement. For a
stand-alone facility, if different medical specialties utilize FGI equipment (e.g., interventional cardiology, interventional radiology, vascular surgery), the facility should
consider including physicians and technologists from
each specialty. Other possible committee members are
department managers, health system risk managers,
and the radiation safety officer (RSO). Other individuals
may be added to the committee as deemed necessary.
If a larger healthcare system has more than one facility,
a system-wide committee may be established to ensure
consistency among facilities. In this structure, one RPC
may be formed, provided each facility within the enterprise has appropriate representation on the committee.
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Another option is to add the scope of the RPC into
the responsibilities of an already established Radiation
Safety Committee, as long as the recommended RPC
membership is met.
Per the SSRs, the RPC is responsible for establishing
procedures and protocols to be followed before, during,
and after FGI procedures. The SSRs state that protocols
addressing the following are reviewed by the committee
at least annually:

to the RPC. Some events may prompt the need for ad
hoc meetings, such as sentinel events or serious patient
injury review, per the previous NCRP Statement 11 QAPR discussion.45
The SSRs suggest that the RPC provide an annual
report to the radiation safety committee, or, if the facility
does not have a radiation safety committee, to the RSO.
Although not addressed in the SSRs, this MPPG recommends that the annual report contain the following:

1.
2.
3.
4.
5.

1. A list of individuals authorized to use fluoroscopic
equipment for FGI procedures.
2. The total number of procedures that exceeded the
SRDL and, if available, percentage of total procedures.
3. A review of all policies and procedures and any significant changes.

Authorized users of FGI equipment.
Intra-procedure patient radiation dose monitoring.
Dose notification levels.
Establishment of SRDL values.
Actions to be taken when a SRDL is exceeded.

These protocols are discussed elsewhere in this
report. The SSRs only require the RPC to create and
implement policies and does not require committee
oversight of clinical data. However, given the membership, it is the recommendation of this MPPG that such
review fall under RPC oversight. This review includes
evaluation of clinical and dosimetric data from any procedure in which the SRDL is exceeded or a tissue reaction has occurred, as well as analysis of facility or system case volume and dose index datasets, described
in a later section. These datasets can include case volume and comparative dosimetry. The duties of the RPC
could also be extended to include the previously discussed QA-PR functions.45 In doing so, the committee reviews procedure justification, patient-specific factors, radiation dose optimization, the time course over
which radiation doses were administered,disease severity, and procedure complexity.45 Depending upon the
size of the healthcare system, initial oversight might
better be accomplished by department-level committees. Under such a framework, each individual department (e.g., interventional cardiology, interventional radiology, vascular surgery), would have its own committee
to oversee clinical and dosimetric data, and to perform
QA-PR review of the clinical appropriateness of procedures resulting in tissue effects. The results of this
department-level review would then be sent to the facility or system-wide RPC for final review and approval.
The healthcare system determines the frequency of
RPC meetings. The SSRs suggest that the committee
meet at least annually. More frequent meetings may
allow for more rapid identification of potential problems
and swifter implementation of subsequent changes in
practice. Considerations that affect meeting frequency
include the duties of the committee, the volume and
complexity of FGI procedures performed, the number of
physicians and medical staff involved, and the capabilities of the imaging equipment. Of these, procedure volume and complexity may be the most important, as both
play a role in the number of potential procedures that
may require committee review, if such review is tasked

9.2

Procedures for maintaining records

The SSRs also recommend that all available radiation
dose indices be recorded to facilitate skin dose estimation, if needed.
These recommendations are similar to TJC requirements previously discussed, and the role of the QMP is
to provide guidance on what specific information must
be recorded for skin dose estimates. If RDSRs are produced by a fluoroscope, they should be archived, if possible, and the QMP must have access to them when
needed. Where the RSDR is not available, the QMP
may request that additional information be recorded,
such as gantry angles, fluoroscopic technique factors,
table height, patient dimensions, etc. Appropriate patient
follow-up procedures,including skin dose estimation,are
performed according to policies set forth by the committee.

9.3
Facility dataset review for quality
improvement
Beyond CRCPD recommendations and TJC standards
to review and analyze procedures over threshold values,
collection of fluoroscopic dose index data provides facilities with quality improvement opportunities, as these
data can be used to evaluate clinical practice. This type
of analysis is useful because dose to the patient in
fluoroscopy is highly dependent on the operator of the
equipment. Since the QMP often oversees the collection
of fluoroscopic data, they are well positioned to handle
the task of data analysis. As detailed in NCRP Report
168, these data can be used to build “facility datasets”for
each type of exam performed in a practice that can be
compared among sites or to normative datasets, such
as the American College of Radiology Fluoroscopy
Dose Index Registry (DIR).1 These analyses can
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provide valuable insight into how the equipment is being
used clinically and identify deviations from expected
practice. NCRP Report No. 168 also recommends
calculating the percentages of each procedure that
exceed the SRDL set by the facility.1 This process can
help determine those procedures that are more likely to
result in high doses to patients. This information has the
potential to affect the pre-procedure consent process
and room assignment decisions. Fluoroscopy dose
index data may also be used to set procedure-specific
dose index review levels for evaluating clinical practice.
These are not to be confused with the SRDL, which is a
biologically based threshold related to the potential for
tissue effects. Procedure-specific review levels represent target achievable dose indices for specific procedures and can be useful for comparing clinical practice.
Beyond reported indices, collected data can be used
to derive additional metrics for practice insight. Dividing Ka,r by total fluoroscopy time yields a measure of
radiation utilization efficiency for a particular procedure,
assuming fluoroscopy time is in some way related to
the complexity of the procedure. For two procedures
of similar complexity and fluoroscopy time, a procedure
with higher utilization of acquisition or high-level control modes would yield a higher value. Additionally, total
PKA and Ka,r data can be used to calculate the average field size (PKA /Ka,r ) at the IRP/PERP for a given
procedure, thus permitting comparison of an operator’s
use of collimation. Beyond individual procedures, these
derived metrics can be calculated for a fluoroscope or
operator over a given month or quarter to assess and
compare longer term operational trends. Values of any
metric found to be substantially different from facility
benchmarks can be investigated for potential protocol
optimization or practice review. QMPs need to be mindful of the units used for a given dose index when comparing data. While Ka,r is often reported in units of
mGy, displayed PKA values vary by manufacturer and
even by model, necessitating unit conversion for valid
comparisons.
However, differences in procedural dose index data do
not necessarily indicate improper practice. It is likely that
more experienced physicians perform a larger share of
more complex procedures, which would affect their data.
A similar situation can arise with equipment, where a
newer Interventional Radiology (IR) suite with more features is rightfully utilized more often for complex procedures than older equipment. Additionally, patient body
habitus and anatomy can drastically affect dose indices.
Individual procedures may exceed SRDLs not because
they were performed improperly, but because larger
patients or complicated vascular anatomy require higher
tube outputs or longer procedure time.
The results of this type of analysis can be presented
to operators or department chairs on a regular basis,
either through a fluoroscopic RPC or dose review committee, or through other means such as existing staff
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meetings, radiation safety committee meetings, QA-PR
committee, or morbidity and mortality (M&M) conferences. This feedback can be an important part of practice improvement. Beyond comparing data within a practice, comparison to outside practices may be possible
through programs such as the ACR Fluoroscopy DIR.
The ACR Fluoroscopy DIR is the latest addition to the
National Radiology Data Registry, and the first modality to join computed tomography (CT) in the DIR. The
Fluoroscopy DIR provides a continuously updated normative dataset for fluoroscopically guided procedures,
which can be used as an advisory dataset to which participating sites can compare their facility datasets of fluoroscopy dose indices.
The ability of a hospital to perform this kind of analysis will be heavily dependent on the resources available.
If full procedure records, including the exam type, fluoroscope used for the procedure, operator, and available
dose indices are electronically captured, datasets can
be created and evaluated with relative ease. However,
this level of investigation is not practical if paper logs are
used to meet documentation requirements. If resources
are limited, analysis should focus on higher dose FGI
procedures, as they present the greatest radiation risk.
However, if fluoroscopy data for all equipment are being
collected electronically, further evaluations for basic fluoroscopy rooms and mobile C-arms and their operators
can be performed without significant additional effort.

10
ADDITIONAL FGI RELATED QMP
DUTIES
The following sections briefly discuss QMP fluoroscopy
duties beyond patient dose management and serve to
direct the reader to related resources.

10.1
Training and privileging of
fluoroscopy users
Training in the safe use of fluoroscopy, credentialing, and
privileging of fluoroscopy users are important aspects
of patient and staff radiation safety. Privileges identify
which medical procedures a staff member may perform,
while credentialing involves gathering relevant data for
privileging an applicant. The ACR and AAPM recommend that each facility have a policy for granting privileges for fluoroscopy use, and CRCPD SSRs suggest
this policy be developed by the RPC.19,47 The QMP
should be involved in the following tasks as they apply
to the training and credentialing of fluoroscopy users:
determining the need for a credentialing program, developing a fluoroscopy privileging policy, verifying compliance with requirements, developing and maintaining
didactic content, and providing in-person training on the
safe use of fluoroscopy equipment. The nature of the
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training may be dictated by the specific scenario (e.g.,
new FGI operator vs. renewal, or FGI training vs. mini Carm training) as well as state regulations.Specific details
of the QMP’s role are beyond the scope of this practice guideline, but a comprehensive review is provided
in AAPM Report No. 124.48

10.2
Occupational dose monitoring
and badging
Personnel involved in interventional fluoroscopy procedures often require occupational radiation monitoring according to state regulations. For a given healthcare system, oversight of occupational dosimetry may
be the responsibility of the QMP or a separate RSO.
Even if not a direct job duty, the QMP may have better insights into clinical FGI practice and can aid in setting up a dosimetry program and can help verify the
following:

10.2.1
Appropriate personnel are
monitored
Most state regulations mirror the SSR language that
require monitoring of anyone likely to exceed 10% of
the annual occupational dose limits.49 In an FGI environment, operators, be they physicians or technologists,
generally require monitoring as they are likely to exceed
the 5 mSv (500 mrem) effective dose equivalent (EDE)
threshold, which is 10% of the annual (EDE) limit of
50 mSv (5000 mrem). However,depending on local practice and positioning during procedures, ancillary personnel such as nurses or anesthetists often record annual
doses well below the 5 mSv threshold for monitoring.
Ancillary personnel are often positioned farther from
the patient during fluoroscopy and can be behind additional protective measures such as rolling shields. Previous dosimetry histories must be investigated in order to
determine which personnel groups require monitoring.
Monitoring policies may need to be reevaluated when
practices or volumes change.

10.2.2

Monitoring devices are appropriate

Dosimetry service providers must be accredited by the
National Voluntary Laboratory Accreditation Program
(NVLAP) for the type of radiation for which monitoring
is performed. A one- or two-badge protocol can be used
to monitor occupational dose. Single monitoring devices
are worn at the neck/collar outside any radiation personal protective equipment (PPE). The readings from
this badge are directly used to calculate the various personal dose equivalents. Some states allow modification
of measured deep dose equivalent according to equa-

tions in the SSRs and in NCRP Report Nos. 122 and
168 to account for the presence of PPE to derive a more
accurate EDE (HE ).49 This modification results in lower
annual HE readings compared to an un-modified deep
dose,which can be advantageous for workers approaching annual limits. The QMP must verify if this correction
is allowed, as state regulations vary, and sometimes the
correction can only be used in cases where the reported
dose exceeds 25% of annual limits.
With a two-badge protocol, a second monitoring
device is issued and worn underneath the protective garment at the waist. A two-badge protocol best represents
the occupational dose to the worker and will result in
lower HE values than a corrected single-badge protocol,
though again,this may not be allowed by local regulation.
Even when allowed, the two-badge protocol has the disadvantage of requiring twice as many badges. In addition to greater cost and administrative burden, the twobadge protocol increases the risk of lost or improperly
used badges. Wearers often inappropriately mix up the
collar and waist badges, leading to faulty data. A recent
large scale review of occupational dose data from FGI
areas noted that over a third of individual entries from
two-badge wearers were invalid due to either improper
badge use, or failure to return both badges.50 Due to
these likely operational problems with double badging,
this MPPG recommends that a single-badge protocol be
used in FGI environments, with modifications to badge
readings applied to account for the presence of leaded
PPE whenever possible.
Doses to the extremities and skin (shallow dose equivalent) and lens of the eye (lens dose equivalent) are
estimated by the dosimetry service provider based on
the dose received by the monitoring device worn at the
neck. Some dosimetry providers allow for corrections
to lens dose to account for the use of leaded eyewear.
Some also provide separate monitors that attach to eyeglass. Lens dose should be assessed, as evidence has
shown a lower threshold for radiation-induced cataract
than previously thought.51,52 The ICRP has lowered the
annual dose limit to the lens to 20 mSv/year, compared
to the 150 mSv limit in place in the United States. The
NCRP has recommended a 50 mSv annual limit.53 The
previous large scale study found that over 15% of workers exceeded the ICRP limit to the lens.50 The study
found no difference in reported eye dose between a oneor two-badge protocol.

10.2.3
Monitoring frequency is
appropriate
Any state regulatory requirements regarding monitoring
frequency must be followed. Monthly monitoring is recommended as it permits more timely identification and
investigation of high doses than does bimonthly or quarterly monitoring. However, less frequent monitoring may
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be appropriate for groups with lower occupational doses
to reduce costs and administrative burden.

10.2.4
Monitoring devices are used
correctly by staff
Each individual should wear their assigned monitoring device(s) during procedures, at the correct location
on their body and in the correct position with respect
to the protective apron. When not in use, monitoring
devices are stored in a location where they are not
exposed to radiation above background levels. Control
badges should not be exposed to radiation above background levels. Monitoring devices are exchanged, or
data are retrieved from electronic monitoring devices in
a timely manner. During the previously described observations of clinical FGI procedures,the QMP can observe
occupational dosimetry usage and offer suggestions for
improvement.

10.2.5

Monitoring results are reviewed

Doses received by monitored employees should be
reviewed at least quarterly to identify exposures above
the facility’s As Low as Reasonably Achievable (ALARA)
investigational levels and regulatory limits. Local regulations and accreditation body requirements must be followed. Regular dose review can identify trends, opportunities for dose reduction, and possible non-compliance
issues relating to badge misuse or nonuse. Feedback to
users, department chairs, and the RPC on the results
of dosimetry review are an important part of quality
improvement. The review may be done by the QMP, the
RSO, or an individual delegated this responsibility by the
QMP or RSO. Even in circumstances where an RSO
oversees monitoring results, the QMP can provide additional radiation protection guidance to FGI participants
though didactic or hands on demonstrations.

10.2.6
Occupational radiation exposures
meet regulatory requirements
Results should be compared to limits in state regulations, the US Nuclear Regulatory Commission (NRC)
regulations, or, if applicable, United States Occupational
Safety and Health Administration (OSHA) limits.54,55
Mandatory reporting to applicable regulatory bodies
must be performed if dose limits are exceeded.

10.3

Institutional review board

QMPs in academic or research settings may be tasked
with participation in hospital institutional review boards

(IRB), which oversee human research studies and
ensure ethical treatment of participants. Most often, the
QMP serves to provide dose and risk estimates for
imaging research studies that differ from standard of
care. NCRP Report No. 185, “Evaluating and Communicating Radiation Risks for Studies Involving Human
Subjects: Guidance for Researchers and Institutional
Review Board” provides useful information for QMPs
serving this capacity.18

11

CONCLUSION

QMPs have a major role in helping healthcare institutions manage modern FGI practices. Their expertise related to the equipment, radiation biology, and
regulatory environment surrounding fluoroscopy makes
them an invaluable member of clinical team. QMPs
can help in the development and implementation of
appropriate protocols for managing patient radiation
dose before, during, and after potentially high-dose FGI
procedures, as well as oversee analysis of clinical
dose index data to further improve practice. Through
educational efforts, QMPs can ensure that all clinical staff are appropriately informed of the potential radiation risks from fluoroscopic procedures so
that appropriate measures can be taken to minimize risks and maximize benefits for patients and
staff.
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APPENDIX A
High-dose fluoroscopy sample consent language
You have been scheduled for a procedure that uses Xrays, which are a type of radiation. Your doctor believes
that the benefits of this procedure exceed the very small
risks that may be associated with this use of radiation.
Skin changes like redness and hair loss are examples
of the possible risks from radiation. These usually go
away in a few days. In rare cases, they may be more
severe. The risk of these skin changes depends on how
much radiation is used.
You or your family will be told after the exam if skin
changes are likely.If this happens,you will be given more
instructions. These will tell you how to check your skin
and what you should do if you see any changes.
APPENDIX B
High-dose fluoroscopy discharge instructions
The procedure you had was done with X-rays.X-rays are
a type of radiation.Because the procedure was complex,
it required the use of more X-rays than other types of
imaging, such as a chest X-ray or CT scan.
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There is a chance that the X-rays could cause skin
changes in the area that was treated. These skin
changes usually go away within a few days. Rarely, the
skin changes can be more severe.
Over the next month, please check your skin in the
treated area indicated above and watch for any of the
following:

1.
2.
3.
4.

A red area, about the size of your hand.
Flaking skin, like a sunburn.
Small areas of hair loss.
Constant itching in the same area.

If you see any of these signs, please contact us
as soon as possible to determine if any treatment
is needed, or if the changes will get better without
treatment.

